GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Most kinase inhibitors are designed to bind to highly homologous ATP-binding sites, which leads to promiscuity and possible off-target effects. Allostery is an alternative approach to pursuing selectivity. However, allostery is difficult to exploit due to the wide variety of underlying mechanisms and the potential involvement of long-range conforma...
Alternative Titles
Full title
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10139115
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10139115
Other Identifiers
ISSN
1422-0067
E-ISSN
1422-0067
DOI
10.3390/ijms24087541
